Floatz logo

Catequentinib

Digestive System Diseases

Zhejiang UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Digestive System Diseases cohort.

Asset / SponsorPhaseRating
Empagliflozin
Yonsei University
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Cedars-Sinai Medical Center
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Cedars-Sinai Medical Center
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB

View all 44 →

Same molecule, other indications

Catequentinib is also rated in:

AnlotinibDormant
BB
Indicative ·
71 / 100
View asset →
refractory malignant neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
kidney cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →